Hero
Arterial hero mobile

ArtixASCEND Study

The Artix All-in-one Solution for Complete thrombEctomy with eNDovascular approach Study

This study is a post-market, prospective, multicenter, single-arm trial to evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with acute lower extremity arterial occlusions.

Evaluation icon

Objective

  • Evaluate the safety and effectiveness of the Artix Thrombectomy System in patients with lower extremity arterial occlusions
     

     
     
People icon

Design

Prospective, single-arm, multicenter trial

  • Up to 250 patients at up to 50 US sites

     

     
Person icon

Primary endpoints

  • Effectiveness: Revascularization rate post-index procedure of target treatment area determined by an independent core lab
  • Safety: Periprocedural device-related major bleeding rate adjudicated by an independent medical monitor
Group of people icon

Key eligibility criteria

  • Acute symptom duration ≤14 days
  • Lower limb arterial occlusion below inguinal ligament
  • Target lesion in native vessels
  • Rutherford category I, IIa, or IIb
Care icon

Other endpoints

  • All-cause mortality
  • Limb salvage
  • Distal embolization SAEs
  • Adjunctive therapy
  • Blood loss
Hospital icon

Duration of patient follow-up

  • Patients are assessed at discharge, 1 month, 3 months, and 6 months